NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
GlobeNewswire
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the..
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the..
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
- Dosing of first..